ANI Pharmaceuticals (ANIP) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

ANI Pharmaceuticals

NasdaqGM•Healthcare•Drug Manufacturers - Specialty & Generic

$76.14+0.75(0.01%)Market closed

Market Cap

$1.61B

P/E

14.9x

P/S

1.6x

P/B

2.7x

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

How this company scores

ExcellentMetricSide Score: 93/100

Strongest: Cash & Earnings Quality (25/25); weakest: Growth (22/25).

Profitability22/25

Growth22/25

Balance Sheet & Red Flags24/25

Cash & Earnings Quality25/25

Strengths

Growing revenueRising free cash flowStrong marginsHigh ROE

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 14.9x5y range 14.9x – 81.9x

Currently below its 8-quarter median.

P/S · 1.6x5y range 1.6x – 2.7x

Currently near its 20-quarter median.

P/B · 2.7x5y range 1.4x – 3.6x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Share Dilution

Red Flag

Shares outstanding increased 9.0% — significant dilution, likely from stock compensation or capital raises.

Price & Volume

Market Cap $1.61B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $978.38M
Q. Revenue: $266.04M
TTM EBITDA: $236.16M
TTM Op. Income: $150.35M
Q. Op. Income: $40.46M
TTM Net Income: $108.31M
Q. Net Income: $24.71M
EPS: $1.09
Shares Out.: $21.16M

$978.38M in TTM revenue grew 30.9% YoY, reaching $266.04M last quarter. TTM EBITDA of $236.16M and TTM operating income of $150.35M show growth is flowing through to the bottom line. TTM net income of $108.31M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 62.4%
EBITDA Margin: 22.6%
Op. Margin: 15.2%
Net Margin: 9.3%

Op. margin of 15.2% is up 8.6% YoY — cost efficiency is improving. Net margin at 9.3% and gross margin of 62.4% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 131% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 14.9x
P/S Ratio: 1.6x
P/B Ratio: 2.7x

At 14.9x P/E, the stock trades below typical market levels. P/S of 1.6x and P/B of 2.7x provide additional context. P/E sits below typical market levels while revenue is growing. Across the last 4 quarters, P/E has fallen for 3 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.49B
Cash: $360.21M
Long-Term Debt: $280.15M
Book Value: $597.21M
D/E Ratio: 0.5
Debt/EBITDA: 4.7

With $1.49B in assets and $280.15M in long-term debt, D/E is 0.5and book value is $597.21M — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 7 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $56.67M
TTM Free Cash Flow: $172.99M
FCF Margin: 17.7%
FCF / Net Income: 1.6

TTM FCF of $172.99M on $56.67M in operating cash flow. The FCF / Net Income ratio of 1.6x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 38% — a weakening trend.